{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:12:38Z","timestamp":1740136358269,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171399"],"award-info":[{"award-number":["82171399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10072-024-07601-w","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T06:02:31Z","timestamp":1716444151000},"page":"5033-5041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic value of antibody concentration ratio for treatment-refractory myasthenia gravis"],"prefix":"10.1007","volume":"45","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haobin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-2544","authenticated-orcid":false,"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"4","key":"7601_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/mus.20030","volume":"29","author":"JC Keesey","year":"2004","unstructured":"Keesey JC (2004) Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29(4):484\u2013505","journal-title":"Muscle Nerve"},{"issue":"11","key":"7601_CR2","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26(11):1054\u20139","journal-title":"Neurology"},{"issue":"1","key":"7601_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","volume":"1412","author":"A Evoli","year":"2018","unstructured":"Evoli A, Alboini PE, Damato V et al (2018) Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci 1412(1):82\u201389","journal-title":"Ann N Y Acad Sci"},{"key":"7601_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","volume":"48\u201349","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B (2014) Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 48\u201349:143\u2013148","journal-title":"J Autoimmun"},{"issue":"2","key":"7601_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","volume":"9","author":"E Cort\u00e9s-Vicente","year":"2022","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Pla-Junca F et al (2022) Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol 9(2):122\u2013131","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"7601_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC (2019) Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol 15(2):113\u2013124","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"7601_CR7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","volume":"267","author":"J Rath","year":"2020","unstructured":"Rath J, Brunner I, Tomschik M et al (2020) Frequency and clinical features of treatment-refractory myasthenia gravis. J Neurol 267(4):1004\u20131011","journal-title":"J Neurol"},{"key":"7601_CR8","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"7601_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/mus.27521","volume":"65","author":"D Veltsista","year":"2022","unstructured":"Veltsista D, Kefalopoulou Z, Tzartos J, Chroni E (2022) Autoantibody profile in myasthenia gravis patients with a refractory phase. Muscle Nerve 65(5):607\u2013611","journal-title":"Muscle Nerve"},{"issue":"9","key":"7601_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","volume":"92","author":"Y Kojima","year":"2021","unstructured":"Kojima Y, Uzawa A, Ozawa Y et al (2021) Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome. J Neurol Neurosurg Psychiatry 92(9):963\u2013968","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"39","key":"7601_CR11","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e242","volume":"36","author":"S Jeong","year":"2021","unstructured":"Jeong S, Noh Y, Oh IS, Hong YH, Shin JY (2021) Survival, Prognosis, and Clinical Feature of Refractory Myasthenia Gravis: a 15-year Nationwide Cohort Study. J Korean Med Sci 36(39):e242","journal-title":"J Korean Med Sci"},{"issue":"4","key":"7601_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","volume":"49","author":"DB Sanders","year":"2014","unstructured":"Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L (2014) Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis. Muscle Nerve 49(4):483\u2013486","journal-title":"Muscle Nerve"},{"issue":"3","key":"7601_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","volume":"58","author":"HJ Oosterhuis","year":"1983","unstructured":"Oosterhuis HJ, Limburg PC, Hummel-Tappel E, The TH (1983) Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci 58(3):371\u201385","journal-title":"J Neurol Sci"},{"issue":"12","key":"7601_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114060","volume":"9","author":"AT Heldal","year":"2014","unstructured":"Heldal AT, Eide GE, Romi F, Owe JF, Gilhus NE (2014) Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PLoS ONE 9(12):e114060","journal-title":"PLoS ONE"},{"issue":"4","key":"7601_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 87(4):419\u2013425","journal-title":"Neurology"},{"issue":"4","key":"7601_CR16","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/ene.14675","volume":"28","author":"C Tran","year":"2021","unstructured":"Tran C, Biswas A, Mendoza M, Katzberg H, Bril V, Barnett C (2021) Performance of different criteria for refractory myasthenia gravis. Eur J Neurol 28(4):1375\u20131384","journal-title":"Eur J Neurol"},{"issue":"5","key":"7601_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mus.23988","volume":"49","author":"HD Katzberg","year":"2014","unstructured":"Katzberg HD, Barnett C, Merkies IS, Bril V (2014) Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve 49(5):661\u2013665","journal-title":"Muscle Nerve"},{"issue":"2","key":"7601_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ene.13189","volume":"24","author":"T Kanai","year":"2017","unstructured":"Kanai T, Uzawa A, Kawaguchi N et al (2017) Adequate tacrolimus concentration for myasthenia gravis treatment. Eur J Neurol 24(2):270\u2013275","journal-title":"Eur J Neurol"},{"issue":"12","key":"7601_CR19","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C (2020) Patient-acceptable symptom states in myasthenia gravis. Neurology 95(12):e1617\u2013e1628","journal-title":"Neurology"},{"issue":"1","key":"7601_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16\u201323","journal-title":"Neurology"},{"key":"7601_CR21","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T (2019) Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 12:1756286419832242","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"7601_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 96(3):114\u2013122","journal-title":"Neurology"},{"issue":"6","key":"7601_CR23","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/ene.14820","volume":"28","author":"R \u00c1lvarez-Velasco","year":"2021","unstructured":"\u00c1lvarez-Velasco R, Guti\u00e9rrez-Guti\u00e9rrez G, Trujillo JC et al (2021) Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. Eur J Neurol 28(6):2083\u20132091","journal-title":"Eur J Neurol"},{"issue":"3","key":"7601_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1212\/WNL.28.3.266","volume":"28","author":"J Newsom-Davis","year":"1978","unstructured":"Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG (1978) Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 28(3):266\u2013272","journal-title":"Neurology"},{"issue":"4","key":"7601_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jca.21694","volume":"34","author":"Usmani A, Kwan L, Wahib-Khalil D, Trivedi J, Nations S, Sarode R","year":"2019","unstructured":"Usmani A, Kwan L, Wahib-Khalil D, Trivedi J, Nations S, Sarode R (2019) Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status. J Clin Apher 34(4):416\u2013422","journal-title":"J Clin Apher"},{"issue":"1","key":"7601_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis Nat Rev Dis Primers 5(1):30","journal-title":"Myasthenia gravis Nat Rev Dis Primers"},{"issue":"1\u20132","key":"7601_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cccn.2005.05.035","volume":"364","author":"R Hewer","year":"2006","unstructured":"Hewer R, Matthews I, Chen S, McGrath V, Evans M, Roberts E et al (2006) A sensitive non-isotopic assay for acetylcholine receptor autoantibodies. Clin Chim Acta 364(1\u20132):159\u2013166","journal-title":"Clin Chim Acta"},{"issue":"10","key":"7601_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1756285617721093","volume":"10","author":"C Schneider-Gold","year":"2017","unstructured":"Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R (2017) Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience. Ther Adv Neurol Disord 10(10):339\u2013341","journal-title":"Ther Adv Neurol Disord"},{"key":"7601_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jneuroim.2008.06.027","volume":"201\u2013202","author":"ME Hill","year":"2008","unstructured":"Hill ME, Shiono H, Newsom-Davis J, Willcox N (2008) The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics. J Neuroimmunol 201\u2013202:50\u201356","journal-title":"J Neuroimmunol"},{"issue":"5","key":"7601_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","volume":"33","author":"MC Dalakas","year":"2020","unstructured":"Dalakas MC (2020) Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol 33(5):545\u2013552","journal-title":"Curr Opin Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07601-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07601-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07601-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:26:10Z","timestamp":1727184370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07601-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7601"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07601-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"29 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study complied with the Declaration of Helsinki. All participants were informed and signed the consent form for the study and was approved by the Medical Ethics Committee of the Hunan Medical Science Research Institute of Xiangya Hospital (202103207).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants were informed and signed the consent form for the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}